{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04690322",
            "orgStudyIdInfo": {
                "id": "STU-2020-1378"
            },
            "organization": {
                "fullName": "University of Texas Southwestern Medical Center",
                "class": "OTHER"
            },
            "briefTitle": "POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies",
            "officialTitle": "POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies",
            "therapeuticArea": [
                "Other"
            ],
            "study": "pocus-hemostatic-potential-and-joint-health-in-patients-with-severe-hemophilia-a-on-novel-replacement-therapies"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-04-15",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-07",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-07",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-12-27",
            "studyFirstSubmitQcDate": "2020-12-27",
            "studyFirstPostDateStruct": {
                "date": "2020-12-30",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-15",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-16",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Jessica Garcia",
                "investigatorTitle": "Assistant Professor",
                "investigatorAffiliation": "University of Texas Southwestern Medical Center"
            },
            "leadSponsor": {
                "name": "University of Texas Southwestern Medical Center",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a prospective, randomized control trial in which each patient will be randomly assigned to receive either extended half-life factor VIII based replacement therapy or non-FVIII based replacement therapy, which are both standard of care treatment for persons with Hemophilia A.",
            "detailedDescription": "This is a research study to find out if there is a difference in the way children with hemophilia A form a clot and also evaluate if they develop tiny bleeds within the joint and subsequently early joint changes when receiving extended half-life factor VIII based replacement therapy vs non-FVIII based replacement as part of their hemophilia treatment to prevent spontaneous joint bleeds.\n\nBoth therapies are standard of care therapies for patients with hemophilia A. The only experimental/research procedures as part of this study include the thrombin generation assay and ultrasound. All other procedures are standard of care."
        },
        "conditionsModule": {
            "conditions": [
                "Hemophilia A",
                "Factor VIII"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Each patient will be randomly assigned to receive either extended half-life factor VIII based replacement therapy or non-FVIII based replacement therapy",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 28,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Extended half-life factor VIII-based replacement therapy",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Subjects who are either already on prophylactic standard half-life FVIII products or have not started prophylactic treatment will be randomized to start prophylactic extended half-life FVIII products or non-factor product (emicizumab). Both therapies are considered the current standard of care.\n\nThe study has 4 planned visits at baseline, 1 month, 6 months, and 12 months. They will coincide with the standard of care visits.",
                    "interventionNames": [
                        "Drug: Eloctate",
                        "Drug: Adynovate"
                    ]
                },
                {
                    "label": "Non-Factor VIII-based replacement therapy",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Subjects who are either already on prophylactic standard half-life FVIII products or have not started prophylactic treatment will be randomized to start prophylactic extended half-life FVIII products or non-factor product (emicizumab). Both therapies are considered the current standard of care.\n\nThe study has 4 planned visits at baseline, 1 month, 6 months, and 12 months. They will coincide with the standard of care visits.",
                    "interventionNames": [
                        "Drug: Emicizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Eloctate",
                    "description": "Eloctate is FDA-approved to treat patients with Hemophilia A. This drug will be used for extended half-life factor VIII-based replacement therapy.",
                    "armGroupLabels": [
                        "Extended half-life factor VIII-based replacement therapy"
                    ],
                    "otherNames": [
                        "ELOCTATE- antihemophilic factor (recombinant), fc fusion protein"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Adynovate",
                    "description": "Adynovate is FDA-approved to treat patients with Hemophilia A. This drug will be used for extended half-life factor VIII-based replacement therapy.",
                    "armGroupLabels": [
                        "Extended half-life factor VIII-based replacement therapy"
                    ],
                    "otherNames": [
                        "ADYNOVATE- antihemophilic factor (recombinant) pegylated"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Emicizumab",
                    "description": "Emicizumab is FDA-approved to treat patients with Hemophilia A. This drug will be used for non-factor VIII-based replacement therapy.",
                    "armGroupLabels": [
                        "Non-Factor VIII-based replacement therapy"
                    ],
                    "otherNames": [
                        "HEMLIBRA- emicizumab injection, solution"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Changes in hemostatic potential",
                    "description": "Evaluate differences in hemostatic potential in persons with hemophilia A without evidence of hemophilic target joints who are receiving prophylactic FVIII-based replacement therapy versus non-FVIII replacement therapy by measuring thrombin generation potential via a plasma-based assay",
                    "timeFrame": "Baseline, 1 month, 6 months, and 12 months from start of study"
                },
                {
                    "measure": "Changes in early joint-health markers",
                    "description": "Identify early joint-health markers associated with bleeding in persons with hemophilia A without evidence of hemophilic target joints who are receiving prophylactic FVIII-based replacement therapy versus non-FVIII replacement by measuring soft tissue and osteochondral changes among 6 joints (bilateral elbows, knees, and ankles) using point of care ultrasound between both treatment groups",
                    "timeFrame": "Baseline, 1 month, 6 months, and 12 months from the start of study"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Changes in bleeding rates",
                    "description": "Measure bleeding rates in persons with hemophilia A without evidence of hemophilic target joints on prophylactic FVIII-based replacement therapy versus non-FVIII replacement therapy by measuring the difference in annualized bleeding rates between the two treatment groups, as well as other surrogate markers of bleeding, or indirect causes of bleeding, which include FVIII inhibitor level, hemoglobin, and serum ferritin",
                    "timeFrame": "Baseline and 12 months after start of study"
                },
                {
                    "measure": "Changes in health-related quality of life and physical activity",
                    "description": "Evaluate health-related quality of life and physical activity in persons with hemophilia A without evidence of hemophilic target joints on prophylactic FVIII-based replacement therapy versus non-FVIII replacement therapy using validated questionnaires",
                    "timeFrame": "Baseline, 1 month, 6 months, and 12 months from the start of study"
                },
                {
                    "measure": "Changes in joint health",
                    "description": "Assess joint health in persons with hemophilia A without evidence of hemophilic target joints on prophylactic FVIII-based replacement therapy versus non-FVIII replacement therapy using validated outcome tool (Hemophilia Joint Health Score)",
                    "timeFrame": "Baseline, 1 month, 6 months, and 12 months from the start of study"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects with moderate hemophilia A (baseline factor VIII activity 1-5%) or severe hemophilia A (baseline factor VIII activity \\<1%) on prophylactic standard half-life FVIII infusions OR subjects with moderate or severe hemophilia A who have not started prophylactic treatment\n* Less than 18 years of age\n\nExclusion Criteria:\n\n* Subjects with documented FVIII inhibitor\n* Subjects with a history of \u2265 2 target joints\n* Subjects with a history of synovectomy\n* Currently using medications known to impact bone and mineral metabolism (e.g., bisphosphonates, corticosteroids, estrogen, testosterone, calcitonin, thyroid hormone therapy);\n* Disease states known to affect bone integrity (e.g., primary hyperparathyroidism, Paget's disease, clinically significant liver disease)",
            "healthyVolunteers": false,
            "sex": "ALL",
            "maximumAge": "17 Years",
            "stdAges": [
                "CHILD"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Jessica Garcia, MD",
                    "role": "CONTACT",
                    "phone": "214-456-7000",
                    "email": "Jessica.Garcia@utsouthwestern.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Jessica Garcia, MD",
                    "affiliation": "University of Texas Southwestern Medical Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "The University of Texas Southwestern Medical Center",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75235",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jessica Garcia, MD",
                            "role": "CONTACT",
                            "phone": "214-456-7000",
                            "email": "Jessica.Garcia@UTSouthwestern.edu"
                        },
                        {
                            "name": "Jessica Garcia, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Ayesha Zia, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Ravi Sarode, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006467",
                    "term": "Hemophilia A"
                }
            ],
            "ancestors": [
                {
                    "id": "D000025861",
                    "term": "Blood Coagulation Disorders, Inherited"
                },
                {
                    "id": "D000001778",
                    "term": "Blood Coagulation Disorders"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000020147",
                    "term": "Coagulation Protein Disorders"
                },
                {
                    "id": "D000006474",
                    "term": "Hemorrhagic Disorders"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9553",
                    "name": "Hemophilia A",
                    "asFound": "Hemophilia A",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21977",
                    "name": "Hemostatic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5059",
                    "name": "Blood Coagulation Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M23095",
                    "name": "Blood Coagulation Disorders, Inherited",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M21982",
                    "name": "Coagulation Protein Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M9560",
                    "name": "Hemorrhagic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "T2710",
                    "name": "Hemophilia",
                    "asFound": "Hemophilia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2711",
                    "name": "Hemophilia A",
                    "asFound": "Hemophilia A",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000005169",
                    "term": "Factor VIII"
                },
                {
                    "id": "C000609799",
                    "term": "BAX 855"
                },
                {
                    "id": "D000018033",
                    "term": "Antibodies, Bispecific"
                }
            ],
            "ancestors": [
                {
                    "id": "D000003029",
                    "term": "Coagulants"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                },
                {
                    "id": "M9576",
                    "name": "Hemostatics",
                    "relevance": "LOW"
                },
                {
                    "id": "M8312",
                    "name": "Factor VIII",
                    "asFound": "Behcet's Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M260344",
                    "name": "BAX 855",
                    "asFound": "Low temperature",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M20194",
                    "name": "Antibodies, Bispecific",
                    "asFound": "Checking",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M6259",
                    "name": "Coagulants",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Coag",
                    "name": "Coagulants"
                }
            ]
        }
    },
    "hasResults": false
}